IP Library Granted Patent US 8,859,265
Granted Patent B2
US 8,859,265 · App. 12/816,692 · Granted Oct 14, 2014

Lateral flow immunoassay device with a more rapid and accurate test result

Inventors: Byeong-woo Bae (Anyang, KR); Bum-joo Ahn (Seoul, KR); Jj-hun Shin (Seoul, KR); Seok-Ki Lee (Incheon, KR); Jin-hee Jang (Anyang, KR)
Assignee: Infopia Co., Ltd.
G01N33/558B01L2300/0636B01J2219/00722
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,859,265
App. No.
12/816,692
Granted
Oct 14, 2014
Kind
B2
Abstract

The present invention provides a lateral flow immunoassay device for qualitative or quantitative analysis of an analyte of interest in a whole blood sample with a more rapid and accurate result. This device includes a sample receiving pad, a conjugate pad, a flow delaying pad and a wicking membrane in this order. A polycation is provided within and bound to the sample receiving pad in order to separate the red blood cell from the whole blood sample. A relation between average pore size (P 1 ) of the sample receiving pad, average pore size (P 2 ) of the conjugate pad, and average pore size (P 3 ) of the flow delaying pad is as follows: P 1> P 2> P 3.

Claims (34)

1. A lateral flow immunoassay device for qualitative or quantitative analysis of an analyte of interest in a whole blood sample, the device comprising:

a base member; and

a horizontal array disposed on said base member, the horizontal array comprising:

(i) a sample receiving pad

being located on one end of the base member,

having pores having an average pore size of 30 to 150 micrometers, which receive a whole blood sample, and

which comprises a polycation which separates a red blood cell from the whole blood sample, thereby impeding passage of the red blood cell;

(ii) a conjugate pad

being distinct from the sample receiving pad,

being in contact with the sample receiving pad,

having pores having an average pore size of 6 to 11 micrometers, and

comprising a diffusively bound conjugate, which forms a first immuno-complex with an analyte of the blood in the conjugate pad, the conjugate comprising

a first binder specific to the analyte, and

a label;

(iii) a flow delaying pad

being distinct from the conjugate pad,

being in contact with the conjugate pad,

having pores having an average pore size of 2 to 5 micrometers, and

which receives from the conjugate pad the blood containing the analyte and the conjugate which are not yet combined each other, and the first immuno-complex; and

(iv) a wicking membrane

being in contact with the flow delaying pad, and

having a second binder, which is immobilized in a test line of the wicking membrane, is specific to the analyte, and which combines with the first immuno-complex to form a second immuno-complex fixed to the test line, and

which receives the blood from the flow delaying pad; and

wherein a relation between average pore size (P 1 ) of the sample receiving pad, average pore size (P 2 ) of the conjugate pad, and average pore size (P 3 ) of the flow delaying pad is as follows: P 1 >P 2 >P 3 .

2. The device of claim 1 , wherein the wicking membrane further comprises a third binder which does not bind to the analyte but binds to the first binder and is immobilized in a control line of the wicking membrane, the control line being located downstream of the test line.

3. The device of claim 1 , wherein the label is a color particle material, a gold nanoparticle, a color-changed enzyme, or a fluorescent material.

4. The device of claim 1 , wherein the analyte is selected from a group consisting of an antibody, an antigen, a nucleic acid aptamer, a hapten, a antigenic protein, DNA, DNA-binding protein, a hormone, a tumor-specific marker and a tissue-specific marker.

5. The device of claim 4 , wherein the first, second and third binder are selected from a group consisting of an antibody, an antigen, a nucleic acid aptamer, a hapten, a antigenic protein, DNA, DNA-binding protein, and a hormone-receptor.

6. The device of claim 1 , wherein said horizontal array further comprises an absorbent pad disposed on the other end of the base member and being contact with the wicking membrane and having pores to absorb the blood from the wicking membrane.

7. The device of claim 1 , wherein said polycation is selected from the group consisting of poly-L-lysine hydrobromide, poly-L-arginine hydrochloride, poly-L-histidine, poly(lysine, alanine) 3:1 hydr5obromide, poly(lysine, alanine) 2:1 hydrobromide, poly(lysine, alanine) 1:1 hydrobromide, poly(lysine, tryptophan) 1:4 hydrobromide, and poly(diallyldimethylammonium chloride).

8. The device of claim 1 , wherein the flow delaying pad is made of a polyvinyl alcohol-bound glass fiber.

9. The device of claim 5 , wherein the first binder is specific to a first epitope or a first ligand of the analyte and the second binder is specific to a second epitope or a second ligand of the analyte.

10. The device of claim 1 , wherein a polyanion for neutralizing the polycation is further provided within and bound to the conjugate pad.

11. The device of claim 10 , wherein the polyanion is selected from dextran sulfate, poly(acrylic acid), poly(sodium-4-styrene sulfonate), poly(vinyl sulfonic acid), poly(methyl methacrylic acid), poly-L-aspartic acid and carboxymethyl cellulose.

Assignments (2)
CHANGE OF NAME Recorded Apr 28, 2017
From: INFOPIA CO., LTD.
To: OSANG HEALTHCARE CO., LTD.
Reel/Frame 042401/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2010
From: BAE, BYEONG-WOO; AHN, BUM-JOO; SHIN, JJ-HUN; LEE, SEOK-KI; JANG, JIN-HEE
To: INFOPIA CO., LTD.
Reel/Frame 024544/0632 →
Priority Claims (1)
KR 10-2009-0111353 · Nov 18, 2009 · national
Continuity (1)
Related Publication 20110117636A1 · May 19, 2011